Allogenica

At Allogenica, we are transforming cell therapies for a healthier tomorrow. Our mission is to 𝗱𝗶𝘀𝗿𝘂𝗽𝘁 𝘁𝗵𝗲 𝘁𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁 𝗹𝗮𝗻𝗱𝘀𝗰𝗮𝗽𝗲 𝗳𝗼𝗿 𝗰𝗮𝗻𝗰𝗲𝗿, 𝗿𝗮𝗿𝗲 𝗱𝗶𝘀𝗲𝗮𝘀𝗲𝘀, 𝗮𝗻𝗱 𝗮𝘂𝘁𝗼𝗶𝗺𝗺𝘂𝗻𝗲 𝗱𝗶𝘀𝗼𝗿𝗱𝗲𝗿𝘀. We're developing a breakthrough cell therapy platform with the potential to: • 𝗥𝗲𝗽𝗹𝗮𝗰𝗲 𝘁𝗿𝗮𝗻𝘀𝗽𝗹𝗮𝗻𝘁𝘀: Providing less invasive, accessible alternatives for thousands of patients who currently have limited treatment options. • 𝗘𝘅𝗽𝗮𝗻𝗱 𝗮𝗰𝗰𝗲𝘀𝘀 𝗳𝗼𝗿 𝗮𝗹𝗹: With predictable safety and efficacy, we aim to make cell therapies available to a a broader patient population. • 𝗗𝗿𝗮𝗺𝗮𝘁𝗶𝗰𝗮𝗹𝗹𝘆 𝗿𝗲𝗱𝘂𝗰𝗲 𝗰𝗼𝘀𝘁𝘀: By streamlining production, we aim to significantly lower the cost of cell therapies, making transformative treatments more accessible globally. 𝐋𝐞𝐚𝐝𝐢𝐧𝐠 𝐂𝐞𝐥𝐥 𝐓𝐡𝐞𝐫𝐚𝐩𝐲 𝐑𝐞𝐯𝐨𝐥𝐮𝐭𝐢𝐨𝐧 Founded in 2022, Allogenica has rapidly emerged as a pioneer in the field. Our innovative approach includes: • 𝗣𝗿𝗼𝗽𝗿𝗶𝗲𝘁𝗮𝗿𝘆 𝗣𝗿𝗲-𝗧 𝗖𝗲𝗹𝗹 𝗧𝗵𝗲𝗿𝗮𝗽𝗶𝗲𝘀: Enhancing compatibility with patients' immune systems, reducing the risk of rejection. • 𝗦𝗰𝗮𝗹𝗮𝗯𝗹𝗲, 𝗕𝗿𝗼𝗮𝗱 𝗔𝗽𝗽𝗹𝗶𝗰𝗮𝘁𝗶𝗼𝗻𝘀: Our platform has the potential to treat a diverse range of diseases, ensuring scalability and reaching more patients in need. • 𝗖𝗼𝘀𝘁-𝗘𝗳𝗳𝗲𝗰𝘁𝗶𝘃𝗲, 𝗥𝗮𝗽𝗶𝗱 𝗦𝗼𝗹𝘂𝘁𝗶𝗼𝗻𝘀: Delivering affordable and faster-to-market therapies, to change lives on a global scale, potentially impacting millions. Allogenica is a preclinical-stage biotechnology company headquartered in Lyon, France. 𝘑𝘰𝘪𝘯 𝘶𝘴 𝘪𝘯 𝘵𝘳𝘢𝘯𝘴𝘧𝘰𝘳𝘮𝘪𝘯𝘨 𝘵𝘩𝘦 𝘧𝘶𝘵𝘶𝘳𝘦 𝘰𝘧 𝘩𝘦𝘢𝘭𝘵𝘩𝘤𝘢𝘳𝘦! #CellTherapy #Biotech #HealthcareInnovation #CancerTreatment #RareDiseases #AutoimmuneDisorders #Lyon